Phase 2 to evaluate safety, tolerability and efficacy of INNA-051 in the prevention of illness due to viral respiratory infectionsStudy…
HELSINKI and NAPLES, Italy, April 09, 2025 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), an immunotherapy company developing novel, adaptable…
Saint Herblain (France) and Schlieren (Zurich), April 9, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine…
HUNTSVILLE, Ala., April 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing…
Burlington, Ontario--(Newsfile Corp. - April 8, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotech…
Montreal, Quebec--(Newsfile Corp. - April 8, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"),…
EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome…
"Oscars® of Science" Awards Six $3 Million Prizes GLP-1 Diabetes and Obesity Discovery | Multiple Sclerosis Causes and Treatments | DNA…
Burlington, Ontario--(Newsfile Corp. - April 3, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian…
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm…